Advair for COPD
Executive Summary
GlaxoSmithKline's Advair Diskus (salmeterol/fluticasone, NDA 21-077) and Flovent Diskus (fluticasone, NDA 20-833) will be reviewed for chronic obstructive pulmonary disease by FDA's Pulmonary-Allergy Drugs Advisory Committee Jan. 17. The products are approved for asthma. The meeting will begin at 8 a.m. at the Holiday Inn in Gaithersburg, Md. The committee will meet in closed session on Jan. 18 to review trade secret information...